FOSUN HEALTH Logo

Bone & Soft Tissue Tumors Diagnosis

catalogue

Bone & Soft Tissue Tumors Diagnosis

Bone & Soft Tissue Tumors Diagnosis

The diagnosis of a bone or soft tissue tumor is made from the tissue, and it is made in an order that the first operation depends on. Imaging defines how far the tumor reaches and what it lies next to; the biopsy is planned together with the removal that will follow it; a specialist pathologist names the tumor and gives it a grade; molecular testing identifies the types defined by a specific change; and staging combines the size, depth, grade and any spread to decide how much treatment is needed.

The first image: what a plain radiograph can and cannot say

When the problem is in a bone, the first investigation is a plain radiograph, and it remains one of the most informative single images in medicine. It shows the position of a lesion within the bone, the pattern of the bone that has been destroyed or laid down, whether the margin between the lesion and normal bone is sharp or indistinct, and whether the outer layer of the bone has been disturbed. Taken together these features narrow the possibilities substantially, and they are the reason a radiograph is never skipped in favour of going straight to a scan.

What a radiograph cannot do is show the soft tissue around the bone in detail. A tumor that has broken out of the bone into muscle, or one that began in muscle and has not touched the bone at all, is largely invisible on it. So the radiograph answers the first question — is there something there, and does it look like it belongs in bone — and then hands over.

When the lump is in the soft tissue rather than in a bone, the pathway starts differently. A radiograph has little to offer, and the first useful investigation is usually an MRI, or an ultrasound where the lump is superficial enough to assess that way. The purpose of the ultrasound in that setting is not to diagnose the tumor but to establish that it is solid rather than a cyst, and to justify the MRI.

MRI, CT and the scans that map the whole region

The MRI is the image that defines the tumor, and one principle governs how it should be requested: it must cover the whole region, not only the lump. A scan that frames just the palpable mass cannot show whether the tumor extends into the compartment next to it, whether it reaches a major vessel or nerve, or whether it has grown along a tissue plane beyond where the fingers can feel. Those are precisely the questions the operation depends on, so the scan is ordered to cover the anatomical region — the whole thigh, the whole lower leg, the whole shoulder area — with the tumor in the middle of the field rather than at its edge.

With contrast, the MRI also shows which parts of the tumor are living and which are not, and it characterises the tissue sufficiently well to distinguish most benign lumps from the ones that need a biopsy. A lipoma of fat and a liposarcoma of fat look different on MRI; so does a simple cyst, a haemangioma and a mature myositis ossificans.

CT adds something MRI cannot, and the two are complementary rather than alternatives. CT shows the mineralised structure of bone in fine detail, which matters when a lesion contains cartilage or bone-forming tissue, and it is the standard way of looking at the chest. Because the lungs are the usual place a sarcoma spreads to, imaging of the chest is part of the assessment of almost every sarcoma — a CT of the chest, not a chest radiograph. PET-CT has a narrower role: it is used when the question is whether there is disease somewhere else, or when a lesion cannot be characterised by other means.

The biopsy: a decision made before the first needle

The biopsy is the step where the diagnosis is actually made, and it is also the step that most often goes wrong for a reason that has nothing to do with technique. The rule that governs it is simple: the track the needle takes is part of the tumor. Whatever tissue the needle passes through on its way in and out is a route along which tumor cells can seed, and that route has to be removed together with the tumor at the operation. A biopsy taken along a path that crosses a compartment which must stay clean, or placed where the later removal cannot include it, converts a straightforward operation into a difficult one.

That is why the biopsy is planned by the team that will carry out the removal, and why the surgeon who will operate should be involved before the tissue is sampled. In practice the biopsy is a core needle biopsy taken through a planned track, under imaging guidance where the lesion is deep or close to something important; an open or incisional biopsy, taking a small piece of the tumor directly, is reserved for the situations where a needle cannot provide enough material. In both cases the entry point is marked so that it can be excised later, and in both cases the sample is sent to a pathologist who expects to do molecular work on it.

The corollary is the sentence patients most need to hear: a biopsy should not be arranged in a hurry at the nearest available place before a tumour service has been involved. Waiting a few days to have it done properly changes nothing about the disease and a great deal about the treatment, because a well-placed biopsy keeps every option open while a badly placed one can close some of them.

Naming the tumor: the pathologist's report

The tissue sample is examined under the microscope by a pathologist who works with these tumors, and the report answers three questions: what the tumor is, how much it resembles normal tissue, and what the cells are doing. The name comes from the tissue the tumor most resembles — bone-forming, cartilage-forming, fatty, smooth muscle, nerve sheath, or none of these. The grade is a measure of how far the cells have departed from normal and how actively they are dividing, and it carries real weight: for most soft tissue sarcomas the grade is one of the strongest indicators of how likely the tumor is to return or to spread.

Grading is not straightforward, and this is one reason the sample should be seen at a centre that handles these tumors regularly. Grading rests on how many cells are dividing, how much of the tumor has died off from lack of blood supply, how much fibrous tissue runs through it and how much it has lost the features of any particular tissue. Two pathologists looking at the same slide can differ on details, and the borderline between a low-grade and a high-grade sarcoma has consequences for treatment.

Alongside the name and the grade, the report will describe the extent of the sample and whether the tumor cells reach its edges. Where an operation has already taken place, the report describes whether the margin of normal tissue around the tumor was free of tumor cells — the measurement that matters most of all, and one that is read from the removed specimen rather than from the biopsy.

Taken together, the name and the grade decide the shape of the treatment. A tumor that responds to systemic drugs will be treated with them; a tumor that does not will be treated by surgery, and adding drugs that do not work would only add side effects. This is why the pathological report, rather than the size of the lump or the appearance on the scan, is the document the treatment is built on.

The molecular tests, and why they are run before treatment

A growing number of sarcomas are defined by a specific change in the genetic material of the tumor cells, and for those tumors the change is not a detail attached to the diagnosis; it is the diagnosis. Testing for it converts an ambiguous description under the microscope into a name, and the name is what selects the treatment.

TestWhat it looks forWhy it changes the plan
Fusion testingA translocation that joins two genes — for example involving EWSR1, SS18 or DDIT3It names a small round cell or spindle cell tumor that cannot be identified confidently by appearance alone
Gene amplificationExtra copies of MDM2 and CDK4It separates a fatty sarcoma from a benign fatty tumor that looks similar
Driver mutationChanges in KIT or PDGFRAIt identifies a tumor with a targeted drug of its own, which becomes the backbone of treatment
Protein lossLoss of INI1 in the tumor cellsIt points to a small group of tumors with a particular behaviour and treatment
Rare fusionsA fusion involving NTRKIt opens a targeted treatment for tumors that carry the change, wherever they started

Two practical rules follow from this. The first is that the tissue has to be adequate and handled properly, which is another reason the biopsy belongs at a centre where molecular work is routine rather than exceptional. The second is that the test should be done on the untreated sample wherever possible: chemotherapy and radiotherapy alter the tissue, and a diagnosis that rests on a molecular change is clearer to establish before treatment than after it. Where a patient has already been treated elsewhere, reviewing the original slides is often the fastest route to an answer.

Staging: what is added together

Staging is the summary of what is known, and it answers two questions at once: how far the tumor has already reached, and how likely it is to return if it is simply removed. Four things are added together to answer them.

  • Size, measured on the imaging rather than by hand. A large tumor is not automatically a worse tumor, but size carries weight in the staging systems.
  • Depth, meaning whether the tumor sits above or below the layer of fibrous tissue that wraps the muscles of a limb. A tumor below that layer behaves differently from one above it, which is why depth is part of the description rather than a detail.
  • Grade, read by the pathologist from the tissue. This is the single strongest tissue-based indicator of how the tumor is likely to behave.
  • Spread, which for most sarcomas means imaging of the chest with CT, and in some types a bone scan or a scan of the regions the tumor tends to reach.

Bone tumors and soft tissue tumors are described with different systems, and this is worth knowing because patients encounter both words. Tumors of bone are usually staged with the surgical system used by musculoskeletal tumor surgeons, which combines the grade with whether the tumor is confined within the bone or has broken into the surrounding soft tissue, and whether it has spread. Soft tissue sarcomas are described with the tumor, node and metastasis system, with grade and depth added. The systems differ because the diseases differ: soft tissue sarcomas spread through the blood, and lymph nodes are involved in only a minority of types, so the node category carries less weight than it does in cancers that spread through lymphatics.

What staging does not do is decide the operation on its own. A small low-grade tumor in the fat of a forearm and a large high-grade tumor deep in the thigh can be given different stage descriptions and still be treated on the same principle — remove the tumor with a margin of normal tissue. What changes is everything around the operation: whether systemic treatment is given first, whether radiotherapy is added, how wide the removal must be, and how the limb is rebuilt afterwards.

How the plan comes together, and in what order

Once the imaging, the biopsy and the pathology report are all available, the treatment is decided by the people who will carry it out rather than by a single specialist working alone. In practice the imaging, the histology and the molecular results are reviewed together, side by side, at a meeting attended by the surgeon who will operate, the radiologist who read the scans, the pathologist who named the tumor and the oncologist who will decide whether systemic treatment comes before the operation.

Three questions are settled there. The first is whether chemotherapy or another systemic treatment should come before the operation; that decision belongs to the tumor type, and for the types that respond it is made before surgery rather than after. The second is how wide the removal has to be, which follows from the extent seen on the MRI and from the type of the tumor. The third is what will be done to reconstruct the limb, which is planned before the tumor is removed rather than improvised once it is out.

For patients coming from abroad, the practical effect is that a complete file — the images themselves, the pathology and molecular reports, the operative notes if an operation has taken place, and the chest imaging — can be reviewed and a written opinion returned within about 48 hours of the file being complete. That opinion states what the imaging shows, what the tissue has established, and what the next step should be; the definitive plan usually requires the tissue to be examined locally as well, because the diagnosis rests on it.

Frequently Asked Questions

Can a scan tell whether the tumor is benign or malignant?

Often it can indicate which is more likely, and sometimes it can say so with confidence, but it cannot replace the tissue. MRI of a fatty lump, for example, distinguishes a benign lipoma from a fatty sarcoma in most cases, and a cyst, a haemangioma or a mature form of post-injury ossification each has a characteristic appearance. But the words 'benign' and 'malignant' are defined by what the cells do, and that is a matter for the microscope. The scan decides who needs a biopsy; the biopsy decides what the tumor is. This is why a report that says the appearances are suspicious does not mean the diagnosis has been made.

Why does the biopsy have to be done at a specialist centre?

Because the biopsy is part of the operation rather than a separate test. The route the needle takes has to be removed with the tumor, so the person taking the sample needs to know where the incision will eventually be and which compartments must stay untouched. A biopsy that crosses the wrong plane or sits where the later removal cannot include it makes the operation more difficult and can put the limb at greater risk. There is also a tissue-handling reason: these tumors are uncommon, and the pathologist who receives the sample should be one who expects to do molecular testing on it. Both considerations are why patients are referred before the biopsy rather than after it.

What does it mean if the biopsy result is inconclusive?

It usually means the sample did not contain enough of the tumor, or that the tumor falls into a group that cannot be named from a small piece of tissue. The response is not to treat on an assumption but to obtain better material — a further, properly planned biopsy, or occasionally a small open sample. In the meantime, molecular testing on what has already been taken sometimes resolves the question, and reviewing the original slides at a centre familiar with these tumors frequently does. An inconclusive biopsy is an inconvenience rather than a dead end, and it is worth resisting the pressure to act on a diagnosis that has not been made.

Do I need a PET-CT?

Usually not for the initial assessment, and this surprises some patients who expect it to be the definitive test. MRI defines the tumor and its relation to the structures around it; CT shows bone detail and is the standard way of imaging the chest, which is where sarcomas most often spread. PET-CT shows where tissue is metabolically active, which is useful in specific situations — when it is unclear whether a finding elsewhere is part of the same disease, when the tumor's type tends to appear in several places, or when other imaging has left the picture uncertain. If a PET-CT has not been suggested, it is generally because the other scans have answered the questions that matter.

Send the imaging and the pathology, get a written view

Upload the radiograph, the MRI and the chest imaging as images rather than only reports, with dates; the biopsy and pathology report in full; any molecular testing already done; the operative notes if an operation has taken place; and the list of medicines. Our sarcoma team will return a written opinion within about 48 hours of the file being complete, setting out what the imaging shows, whether the tissue has been sampled in a way that keeps all options open, and what the next step should be.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

WhatsApp +86 172-7459-8280 · EN / 中文 · 24h within business hours

Follow Fosun Health

Apply for an Appointment

Do you have test results*